|
1
|
Yang H, Testa JR and Carbone M:
Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr
Treat Options Oncol. 9:147–157. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kotova S, Wong RM and Cameron RB: New and
emerging therapeutic options for malignant pleural mesothelioma:
Review of early clinical trials. Cancer Manag Res. 7:51–63.
2015.PubMed/NCBI
|
|
3
|
Robinson BM: Malignant pleural
mesothelioma: An epidemiological perspective. Ann Cardiothorac
Surg. 1:491–496. 2012.
|
|
4
|
Robinson BW and Lake RA: Advances in
malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Becklake MR, Bagatin E and Neder JA:
Asbestos-related diseases of the lungs and pleura: Uses, trends and
management over the last century. Int J Tuberc Lung Dis.
11:356–369. 2007.PubMed/NCBI
|
|
6
|
Scherpereel A, Astoul P, Baas P, Berghmans
T, Clayson H, de Vuyst P, Dienemann H, Galateau-Salle F, Hennequin
C, Hillerdal G, et al: European Respiratory Society/European
Society of Thoracic Surgeons Task Force: Guidelines of the European
Respiratory Society and the European Society of Thoracic Surgeons
for the management of malignant pleural mesothelioma. Eur Respir J.
35:479–495. 2010. View Article : Google Scholar
|
|
7
|
Flores RM, Pass HI, Seshan VE, Dycoco J,
Zakowski M, Carbone M, Bains MS and Rusch VW: Extrapleural
pneumonectomy versus pleurectomy/decortication in the surgical
management of malignant pleural mesothelioma: results in 663
patients. J Thorac Cardiovasc Surg. 135:620–626. 626e621–623. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kostron A, Friess M, Crameri O, Inci I,
Schneiter D, Hillinger S, Stahel R, Weder W and Opitz I: Relapse
pattern and secondline treatment following multimodality treatment
for malignant pleural mesothelioma. Eur J Cardiothorac Surg.
49:1516–1523. 2016. View Article : Google Scholar
|
|
9
|
Baldini EH, Richards WG, Gill RR, Goodman
BM, Winfrey OK, Eisen HM, Mak RH, Chen AB, Kozono DE, Bueno R, et
al: Updated patterns of failure after multimodality therapy for
malignant pleural mesothelioma. J Thorac Cardiovasc Surg.
149:1374–1381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gomez DR, Hong DS, Allen PK, Welsh JS,
Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R and Rice DC:
Patterns of failure, toxicity, and survival after extrapleural
pneumonectomy and hemithoracic intensity-modulated radiation
therapy for malignant pleural mesothelioma. J Thorac Oncol.
8:238–245. 2013. View Article : Google Scholar
|
|
11
|
Gupta V, Krug LM, Laser B, Hudka K, Flores
R, Rusch VW and Rosenzweig KE: Patterns of local and nodal failure
in malignant pleural mesothelioma after extrapleural pneumonectomy
and photon-electron radiotherapy. J Thorac Oncol. 4:746–750. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tsao AS, Mehran R and Roth JA: Neoadjuvant
and intrapleural therapies for malignant pleural mesothelioma. Clin
Lung Cancer. 10:36–41. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sterman DH, Alley E, Stevenson JP,
Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz
SI, et al: Pilot and feasibility trial evaluating immuno-gene
therapy of malignant mesothelioma using intrapleural delivery of
adenovirus-IFNα combined with chemotherapy. Clin Cancer Res.
22:3791–3800. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Friedberg JS, Culligan MJ, Mick R,
Stevenson J, Hahn SM, Sterman D, Punekar S, Glatstein E and Cengel
K: Radical pleurectomy and intraoperative photodynamic therapy for
malignant pleural mesothelioma. Ann Thorac Surg. 93:1658–65;
discussion 1665-7. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Friedberg JS: Photodynamic therapy for
malignant pleural mesothelioma. J Natl Compr Canc Netw. 10(Suppl
2): S75–S79. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vrouenraets MB, Visser GW, Snow GB and van
Dongen GA: Basic principles, applications in oncology and improved
selectivity of photodynamic therapy. Anticancer Res. 23B:505–522.
2003.
|
|
17
|
Dolmans DE, Fukumura D and Jain RK:
Photodynamic therapy for cancer. Nat Rev Cancer. 3:380–387. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pass HI, DeLaney TF, Tochner Z, Smith PE,
Temeck BK, Pogrebniak HW, Kranda KC, Russo A, Friauf WS, Cole JW,
et al: Intrapleural photodynamic therapy: Results of a phase I
trial. Ann Surg Oncol. 1:28–37. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Takita H, Mang TS, Loewen GM, Antkowiak
JG, Raghavan D, Grajek JR and Dougherty TJ: Operation and
intracavitary photodynamic therapy for malignant pleural
mesothelioma: A phase II study. Ann Thorac Surg. 58:995–998. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schouwink H, Rutgers ET, van der Sijp J,
Oppelaar H, van Zandwijk N, van Veen R, Burgers S, Stewart FA,
Zoetmulder F and Baas P: Intraoperative photodynamic therapy after
pleuropneumonectomy in patients with malignant pleural
mesothelioma: Dose finding and toxicity results. Chest.
120:1167–1174. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Friedberg JS, Mick R, Stevenson J, Metz J,
Zhu T, Buyske J, Sterman DH, Pass HI, Glatstein E and Hahn SM: A
phase I study of Foscan-mediated photodynamic therapy and surgery
in patients with mesothelioma. Ann Thorac Surg. 75:952–959. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moghissi K and Dixon K: Photodynamic
therapy in the management of malignant pleural mesothelioma: A
review. Photodiagn Photodyn Ther. 2:135–147. 2005. View Article : Google Scholar
|
|
23
|
Lovell JF, Jin CS, Huynh E, Jin H, Kim C,
Rubinstein JL, Chan WC, Cao W, Wang LV and Zheng G: Porphysome
nanovesicles generated by porphyrin bilayers for use as multimodal
biophotonic contrast agents. Nat Mater. 10:324–332. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jin CS, Lovell JF, Chen J and Zheng G:
Ablation of hypoxic tumors with dose-equivalent photothermal, but
not photodynamic, therapy using a nanostructured porphyrin
assembly. ACS Nano. 7:2541–2550. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jin CS, Cui L, Wang F, Chen J and Zheng G:
Targeting-triggered porphysome nanostructure disruption for
activatable photodynamic therapy. Adv Healthc Mater. 3:1240–1249.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bueno R, Appasani K, Mercer H, Lester S
and Sugarbaker D: The alpha folate receptor is highly activated in
malignant pleural mesothelioma. J Thorac Cardiovasc Surg.
121:225–233. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nutt JE, Razak AR, O’Toole K, Black F,
Quinn AE, Calvert AH, Plummer ER and Lunec J: The role of folate
receptor alpha (FRalpha) in the response of malignant pleural
mesothelioma to pemetrexed-containing chemotherapy. Br J Cancer.
102:553–560. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lovell JF, Liu TWB, Chen J and Zheng G:
Activatable photo-sensitizers for imaging and therapy. Chem Rev.
110:2839–2857. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Edmonds C, Hagan S, Gallagher-Colombo SM,
Busch TM and Cengel KA: Photodynamic therapy activated signaling
from epidermal growth factor receptor and STAT3: Targeting survival
pathways to increase PDT efficacy in ovarian and lung cancer.
Cancer Biol Ther. 13:1463–1470. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bhuvaneswari R, Yuen GY, Chee SK and Olivo
M: Antiangiogenesis agents avastin and erbitux enhance the efficacy
of photodynamic therapy in a murine bladder tumor model. Lasers
Surg Med. 43:651–662. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Weyergang A, Selbo PK and Berg K:
Sustained ERK [corrected] inhibition by EGFR targeting therapies is
a predictive factor for synergistic cytotoxicity with PDT as
neoadjuvant therapy. Biochim Biophys Acta. 1830.2659–2670.
2013.
|
|
32
|
Bhuvaneswari R, Gan YY, Soo KC and Olivo
M: Targeting EGFR with photodynamic therapy in combination with
Erbitux enhances in vivo bladder tumor response. Mol Cancer.
8:942009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gallagher-Colombo SM, Miller J, Cengel KA,
Putt ME, Vinogradov SA and Busch TM: Erlotinib pretreatment
improves photodynamic therapy of non-small cell lung carcinoma
xenografts via multiple mechanisms. Cancer Res. 75:3118–3126. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Postiglione I, Chiaviello A, Aloj SM and
Palumbo G: 5-aminolaevulinic acid/photo-dynamic therapy and
gefitinib in non-small cell lung cancer cell lines: A potential
strategy to improve gefitinib therapeutic efficacy. Cell Prolif.
46:382–395. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kurai J, Chikumi H, Hashimoto K, Takata M,
Sako T, Yamaguchi K, Kinoshita N, Watanabe M, Touge H, Makino H, et
al: Therapeutic antitumor efficacy of anti-epidermal growth factor
receptor antibody, cetuximab, against malignant pleural
mesothelioma. Int J Oncol. 41:1610–1618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Destro A, Ceresoli GL, Falleni M, Zucali
PA, Morenghi E, Bianchi P, Pellegrini C, Cordani N, Vaira V,
Alloisio M, et al: EGFR overexpression in malignant pleural
mesothelioma. An immunohistochemical and molecular study with
clinico-pathological correlations. Lung Cancer. 51:207–215. 2006.
View Article : Google Scholar
|
|
37
|
Garland LL, Rankin C, Gandara DR, Rivkin
SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA and
Borden EC: Phase II study of erlotinib in patients with malignant
pleural mesothelioma: A Southwest Oncology Group Study. J Clin
Oncol. 25:2406–2413. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Agarwal V, Lind MJ and Cawkwell L:
Targeted epidermal growth factor receptor therapy in malignant
pleural mesothelioma: Where do we stand? . Cancer Treat Rev.
37:533–542. 2011. View Article : Google Scholar
|
|
39
|
Okuda K, Sasaki H, Kawano O, Yukiue H,
Yokoyama T, Yano M and Fujii Y: Epidermal growth factor receptor
gene mutation, amplification and protein expression in malignant
pleural mesothelioma. J Cancer Res Clin Oncol. 134:1105–1111. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Union for International Cancer Control
(UICC). TNM Classification of Malignant Tumours. 7.
Wiley-Blackwell; Hoboken: 2009
|
|
41
|
ZenBio I: Human mesothelial cells.
http://www.zen-bio.com/products/cells/mesothelial.php,
Accessed July 18, 2014.
|
|
42
|
ExPASy: the SIB Bioinformatics Resource
Portal. https://web.expasy.org/cellosaurus/CVCL_0372.
|
|
43
|
Jackaman C, Bundell CS, Kinnear BF, Smith
AM, Filion P, van Hagen D, Robinson BW and Nelson DJ: IL-2
intratumoral immunotherapy enhances CD8+ T cells that
mediate destruction of tumor cells and tumor-associated
vasculature: A novel mechanism for IL-2. J Immunol. 171:5051–5063.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
ExPASy: the SIB Bioinformatics Resource
Portal_AE17-sOVA. https://web.expasy.org/cellosaurus/CVCL_LJ85.
|
|
45
|
Cordier Kellerman L, Valeyrie L, Fernandez
N, Opolon P, Sabourin JC, Maubec E, Le Roy P, Kane A, Legrand A,
Abina MA, et al: Regression of AK7 malignant mesothelioma
established in immunocompetent mice following intratumoral gene
transfer of interferon gamma. Cancer Gene Ther. 10:481–490. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Blum W, Pecze L, Felley-Bosco E,
Worthmüller-Rodriguez J, Wu L, Vrugt B, de Perrot M and Schwaller
B: Establishment of immortalized murine mesothelial cells and a
novel mesothelioma cell line. In Vitro Cell Dev Biol Anim.
51:714–721. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kato T, Wada H, Patel P, Hu HP, Lee D,
Ujiie H, Hirohashi K, Nakajima T, Sato M, Kaji M, et al:
Overexpression of KIF23 predicts clinical outcome in primary lung
cancer patients. Lung Cancer. 92:53–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kato T, Lee D, Wu L, Patel P, Young AJ,
Wada H, Hu HP, Ujiie H, Kaji M, Kano S, et al: Kinesin family
members KIF11 and KIF23 as potential therapeutic targets in
malignant pleural mesothelioma. Int J Oncol. 49:448–456. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Castano AP, Demidova TN and Hamblin MR:
Mechanisms in photodynamic therapy: Part two-cellular signaling,
cell metabolism and modes of cell death. Photodiagn Photodyn Ther.
2:1–23. 2005. View Article : Google Scholar
|
|
50
|
Moor AC: Signaling pathways in cell death
and survival after photodynamic therapy. J Photochem Photobiol B.
57:1–13. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Pugh CW and Ratcliffe PJ: Regulation of
angiogenesis by hypoxia: Role of the HIF system. Nat Med.
9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang SC and Hung MC: Nuclear translocation
of the epidermal growth factor receptor family membrane tyrosine
kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Boffetta P, Donaldson K, Moolgavkar S and
Mandel JS: A systematic review of occupational exposure to
synthetic vitreous fibers and mesothelioma. Crit Rev Toxicol.
44:436–449. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Friedberg JS, Simone CB II, Culligan MJ,
Barsky AR, Doucette A, McNulty S, Hahn SM, Alley E, Sterman DH,
Glatstein E, et al: Extended pleurectomy-decortication-based
treatment for advanced stage epithelial mesothelioma yielding a
median survival of nearly three years. Ann Thorac Surg.
103:912–919. 2017. View Article : Google Scholar
|
|
55
|
Rodriguez E, Baas P and Friedberg JS:
Innovative therapies: Photodynamic therapy. Thorac Surg Clin.
14:557–566. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Lovell JF, Jin CS, Huynh E, MacDonald TD,
Cao W and Zheng G: Enzymatic regioselection for the synthesis and
biodegradation of porphysome nanovesicles. Angew Chem Int Ed Engl.
51:2429–2433. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Albanese A, Tang PS and Chan WC: The
effect of nanoparticle size, shape, and surface chemistry on
biological systems. Annu Rev Biomed Eng. 14:1–16. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Weitman SD, Weinberg AG, Coney LR,
Zurawski VR, Jennings DS and Kamen BA: Cellular localization of the
folate receptor: Potential role in drug toxicity and folate
homeostasis. Cancer Res. 52:6708–6711. 1992.PubMed/NCBI
|
|
59
|
Chancy CD, Kekuda R, Huang W, Prasad PD,
Kuhnel JM, Sirotnak FM, Roon P, Ganapathy V and Smith SB:
Expression and differential polarization of the reduced-folate
transporter-1 and the folate receptor alpha in mammalian retinal
pigment epithelium. J Biol Chem. 275:20676–20684. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Toffoli G, Cernigoi C, Russo A, Gallo A,
Bagnoli M and Boiocchi M: Overexpression of folate binding protein
in ovarian cancers. Int J Cancer. 74:193–198. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ross JF, Chaudhuri PK and Ratnam M:
Differential regulation of folate receptor isoforms in normal and
malignant tissues in vivo and in established cell lines.
Physiologic and clinical implications. Cancer. 73:2432–2443. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Evans CO, Young AN, Brown MR, Brat DJ,
Parks JS, Neish AS and Oyesiku NM: Novel patterns of gene
expression in pituitary adenomas identified by complementary
deoxyribonucleic acid microarrays and quantitative reverse
transcription-polymerase chain reaction. J Clin Endocrinol Metab.
86:3097–3107. 2001.PubMed/NCBI
|
|
63
|
Weitman SD, Frazier KM and Kamen BA: The
folate receptor in central nervous system malignancies of
childhood. J Neurooncol. 21:107–112. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Jain RK and Stylianopoulos T: Delivering
nanomedicine to solid tumors. Nat Rev. Clin Oncol. 7:653–664.
2010.
|
|
65
|
Ni NC, Jin CS, Cui L, Shao Z, Wu J, Li SH,
Weisel RD, Zheng G and Li RK: Non-invasive macrophage tracking
using novel porphysome nanoparticles in the post-myocardial
Infarction murine heart. Mol Imaging Biol. 18:557–568. 2016.
View Article : Google Scholar : PubMed/NCBI
|
